The Vermont independent who's seeking the Democratic nomination has been chastised by front-runner Hillary Rodham Clinton for espousing an all-inclusive, government-run system. It's called the "single-payer" plan, loosely modeled on how health care is financed in Canada and most of Western Europe. Clinton accuses Sanders of wanting to "eliminate" popular...» Read More
After more than 25 years, this stock is still a Cramer favorite.
DNA has always been one of my favorite clever ticker symbols on the biopharma beat. Sure, GENE might've made sense for Genentech if it had been listed on the Nasdaq, but DNA was pretty good. But after today DNA is no more.
Oh, the Dendreon investor message boards are on fire! And my inbox has a few sparks. Matthew Herper at Forbes wrote a piece today daring to question the integrity of the all-important data due out sometime next month on DNDN's prostate cancer treatment Provenge.
Plus, Cramer discusses credit-card and drug stocks, as well as the housing bottom.
All of my, ahem, complaining and whining, to put it politely, about the American Society of Clinical Oncology may not have fallen on deaf ears after all.
Art Levinson and Miles White are "Kings of the Jungle." At least Barron's thinks they are. The weekly investment periodical picked the pair as the only two from biopharma to make its annual list of the "30 Most Respected CEOs."
My first week on Twitter has gone pretty well. Despite some Twitter trouble (or should that be twubble?) with website capacity, I've picked up more than 75 followers already.
Normally, the folks at GlaxoSmithKline keep us tightly in the loop when there's news. So, I'm a bit surprised that it took a "tweet" on Twitter this morning to learn that four days ago the company put out a press release that has "Pharma's Market" written all over it.
Pfizer announced this morning that it's raising the income levels for uninsured people to qualify for cheaper or free drugs because of the bad economy.
Overpaying for our prescription drugs just feels like a headache no one needs right now, doesn’t it?
Scientific and medical journals like to keep their distance from the business side of things. That's why I think it's worth noting that a "Perspective" piece--think of it as kind of a newspaper Op-Ed--in "The New England Journal of Medicine" starts by mentioning Pfizer's stock price and its recent proposed acquisition of Wyeth.
Despite my repeated invitations for his first post-jailhouse interview on this blog and through one of his contacts, Sam Waksal didn't respond. Given his Manhattan social scene background it should not, perhaps, come as a surprise that the founder of ImClone Systems decided to have his coming-out party in "New York" magazine.
The overwhelming majority of people who have voted in the “Pharma’s Market” poll about the future of Genentech’s execs and top scientists thinks most of them will eventually bolt.
Last week was a busy week, to say the least, on the Pharma beat - So I was looking forward to the weekend and escaping all things drug-related. But as fate would have it, it ended up being bookended by references to pharma in a couple of surprising venues.
All of a sudden yesterday and today shares of Dendreon —my favorite biotech story—shot up on heavy volume.
Even when picking stocks, cash is king, according to Wouter Weijand from Fortis Investments, who likes US funeral service company Hillenbrand, Swiss healthcare manufacturer Novartis, and Australia’s ANZ Bank.
Shares of Dow component Merck rare getting a nice little shot in the arm this morning on an upgrade by Dr. Tim Anderson at Sanford C. Bernstein. He's putting an "Outperform" or "Buy" rating on MRK and raising his target price three bucks to $30.
Anyone out there who sees hope in the stock market must be on drugs. And I am: Lipitor and Novasc from Pfizer, Vasotec from Merck, and four other pills, all of which I gobble every day to stop myself from blowing a gasket. So let me say, with some personal pill-popping experience, that this may be a great time to buy drug stocks.
Even better: Events that could push the Dow up another 1,000 points.
Plus, Cramer makes the call on Goldman Sachs, General Electric, Apple, Citigroup and more.